Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Levodopa (CVT-301) for Parkinson's OFF Episodes
NCT02240030Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- Nov 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of levodopa in Parkinson's disease (PD) (3 arms), sponsored by Acorda Therapeutics. Primary endpoint: Unified Parkinson's Disease Rating Scale Part III Motor Score. Started Nov 2014; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02240030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240030.